Skip to Main Content

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Securities Fraud Investigation

On March 18, 2025, Sarepta issued a press release revealing that a 16-year-old boy had passed away from acute liver failure following treatment with Sarepta’s gene therapy, ELEVIDYS. 

On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  

Complete this form with your transactions in Sarepta Therapeutics, Inc. securities between June 23, 2023 and March 17, 2025.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Purchase(s)
+ Additional Purchases
Sale(s)
+ Additional Sales
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Sarepta Therapeutics, Inc. prior to the Class Period?
Are you a current or former employee of Sarepta Therapeutics, Inc. ?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email
Submit Your Information